Skip to main content

01-11-2019 | Psoriatic arthritis | ACR/ARP 2019 | Article

Researcher comment: The DISCOVER-2 trial

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape (8:26).


Back to the ACR/ARP 2019 conference hub

Related topics

Telemedicine in rheumatology: COVID-19 and beyond

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Image Credits